Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Nora Volkow.
Page 717
Medical treatment of GEP NETS: Mohamed and Strosberg provide an overview of advances in medical management of gastroenteropancreatic neuroendocrine tumors within the context of the larger multidisciplinary approach to these diseases.
Page 721
Imaging the heart–brain axis: Thackeray offers a look at recent work underlining the still-to-be-elucidated connections between neuroinflammation/long-term brain function and ischemic injury to the heart.
Page 728
Cell therapy imaging: Martinez and colleagues highlight key developments over the last 5 years in cell-based cancer therapies, including the introduction of novel tracers for in vivo tracking.
Page 730
Imaging agent/modality translation: Gambhir and other participants report on a 2017 National Cancer Institute–led meeting of government, professional, and industry groups on phase III studies and pathways of approval, coverage, and reimbursement for new cancer imaging agents and modalities.
Page 736
Dynamic PET/CT in PPGLs: Berkel and colleagues use dynamic 18F-FDG PET/CT imaging to assess whether in vivo 18F-FDG pharmacokinetic assessment offers added value over static PET to distinguish different genotypes in pheochromocytomas and paragangliomas.
Page 745
Tumor lysis syndrome after RLT: Huang and colleagues describe the occurrence of tumor lysis syndrome after radioligand therapy with 177Lu-labeled agents in patients with neuroendocrine tumors and prostate cancer.
Page 752
Fluorescence-guided surgery: Liu and Sanai provide perspective on current approaches, trends, and challenges to the clinical adoption of fluorescence-guided surgery and intraoperative decision making and preview a related article in this issue of JNM.
Page 756
Real-time fluorescence-guided surgery: van Keulen and colleagues assess the clinical utility of real-time fluorescence imaging for intraoperative decision making in patients with head and neck squamous cell carcinoma.
Page 758
Tongue cancer tumor margins: Meershoek and colleagues explore the utility of an indocyanine green–99mTc-nanocolloid tracer for tumor margin demarcation combined with sentinel node biopsy in patients with oral tongue tumors.
Page 764
Characterizing thyroid cancer: De Rose and colleagues validate galectin-3 targeting as a method to detect non–radioiodine-avid thyroid cancer in thyroid orthotopic tumor models and discuss potential advantages over thyroid scintigraphy in distinguishing malignant from benign lesions.
Page 770
64Cu-SARTATE in NETs: Hicks and colleagues perform a first-in-humans trial of PET/CT imaging with this novel somatostatin analog in patients with neuroendocrine neoplasia to assess its safety and ability to localize disease at early and late imaging time-points.
Page 777
68Ga-PSMA-11 metaanalysis: Hope and colleagues detail an updated metaanalysis of reports on 68Ga-PSMA-11 PET staging in prostate cancer, separating imaging at the time of diagnosis from that at biochemical recurrence and focusing on pathology correlation.
Page 786
PET and MR imaging in PCa: Emmett and colleagues assess the ability of 18F-FCH PET/CT, 68Ga-HBED-CC PSMA-11 PET/CT, and pelvic multiparametric MR imaging to identify men with prostate cancer who will best benefit from salvage radiation treatment.
Page 794
68Ga-FAPI PET/CT tumor SUV: Kratochwil and colleagues quantify uptake of a 68Ga-labeled fibroblast-activation-protein inhibitor on PET/CT in various primary and metastatic tumors to identify the most promising indications for future application.
Page 801
Clinical experience with 90Y-PSMA: Rathke and colleagues present dosimetry estimates for 90Y-labeled prostate-specific membrane antigen–617, report first clinical experiences, and discuss advantages and drawbacks of varying the β-emitter in PSMA-targeting radioligand therapy.
Page 806
Exendin-4 for insulinoma therapy: Buitinga and colleagues evaluate the ability of succinylated gelatin to reduce renal accumulation of radiolabeled exendin and estimate maximum absorbed insulinoma doses if exendin were used for peptide-receptor radionuclide therapy.
Page 812
18F-JK-PSMA-7 for PSMA-positive lesions: Zlatopolskiy and colleagues describe development of this highly selective prostate-specific membrane antigen probe and its enhanced imaging properties, with comparisons to 18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11.
Page 817
Patient positioning for cardiac SPECT: Perrin and colleagues report on results of a study assessing myocardial perfusion imaging in a forward-leaning bikerlike position with the high-sensitivity D.SPECT cadmium-zinc-telluride camera.
Page 824
Data-driven GPM detection and correction: Lassen and colleagues investigate the feasibility of an automated data-driven method for detection of gross patient motion during coronary PET acquisition.
Page 830
AD conversion–related network: Blazhenets and colleagues use a principal components analysis to identify a metabolic Alzheimer disease conversion–related pattern in PET data from individuals with mild cognitive impairment and investigate the prognostic value of resulting pattern expression scores.
Page 837
Reproducibility of awake mouse brain PET: Miranda and colleagues develop and validate brain PET imaging techniques for awake, freely moving mice, with radioactive point-source markers used to track head motion for correction.
Page 844
MR and PET/MR index in Crohn’s disease: Li and colleagues describe an 18F-FDG PET/MR enterography index as a hybrid surrogate marker for active ileocolonic inflammation in Crohn’s disease and compare its diagnostic performance with that of validated MR indices.
Page 851
Innate immuno-PET in colitis: Dmochowska and colleagues compare immuno-PET of antibodies to IL-1β and CD11b against standard 18F-FDG and MR imaging approaches in detection of colonic inflammation.
Page 858
PET radiomics optimization: Papp and colleagues report on a radiomics analysis of 18F-FDG PET data to identify feature extraction and imaging protocol parameters that minimize radiomic feature variations across PET imaging systems.
Page 864
- © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.